Schall Law Firm Targets Soleno and Ultragenyx in Securities Fraud Litigation

The biotech sector is facing a fresh wave of legal scrutiny as the Schall Law Firm, a prominent shareholder rights firm, announced the commencement of securities fraud class action lawsuits against Soleno Therapeutics (SLNO) and Ultragenyx Pharmaceutical (RARE). These filings, announced concurrently on March 12, 2026, suggest a coordinated effort by legal counsel to address alleged transparency issues following the most recent corporate earnings cycle. For investors in the high-volatility biotech space, these lawsuits represent a significant development in the ongoing tension between clinical-stage projections and commercial reality.

Soleno Therapeutics has been under the microscope following a series of executive shifts. SEC filings from late February 2026 revealed the departure of key directors and officers, a move that often triggers investor anxiety regarding internal stability or strategic shifts. Soleno’s primary asset, DCCR (Diazoxide Choline Controlled-Release) for the treatment of Prader-Willi Syndrome, has been the cornerstone of its valuation. Any perceived lack of transparency regarding the regulatory path or commercialization strategy for DCCR typically serves as the catalyst for such litigation. The Schall Law Firm's action focuses on whether the company issued false or misleading statements that artificially inflated the stock price before these internal changes became public.

“

The Schall Law Firm's action focuses on whether the company issued false or misleading statements that artificially inflated the stock price before these internal changes became public.

Simultaneously, Ultragenyx Pharmaceutical is grappling with its own legal challenges. The company’s February 12, 2026, regulatory filings disclosed significant 'costs associated with exit or disposal activities,' a technical term often indicating restructuring, facility closures, or the discontinuation of specific pipeline programs. While Ultragenyx has a diverse portfolio, including Crysvita and Dojolvi, the sudden disclosure of restructuring costs can lead to sharp market corrections if investors feel the underlying financial health was misrepresented in previous quarters. The lawsuit alleges that Ultragenyx failed to disclose the full extent of its operational challenges, leading to investor losses when the restructuring was finally unveiled.